Chloroquine Inhibits Processing of Tumor Necrosis Factor in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages

Journal of Immunology

Volumn 158, Issue 10, 1997, Pages 4901-4907

  Jeong, Jae Yeon ^a   Jue, Dae Myung ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEIN PRECURSOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; CELL LINE; DRUG EFFECT; GENE EXPRESSION; GENETICS; LYSOSOME; MACROPHAGE; METABOLISM; MOUSE; PROTEIN PROCESSING;

ANIMALS; CELL LINE; CHLOROQUINE; GENE EXPRESSION; LIPOPOLYSACCHARIDES; LYSOSOMES; MACROPHAGES; MICE; PROTEIN PRECURSORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031569968     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Vassalli, P. 1992. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 1:411.
2. Beutler, B., I. W. Milsark, and A. C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869.
3. Tracey, K. J., B. Beutler, S. F. Lowry, J. Merryweather, S. Wolpe, I. W. Milsark, R. J. Hariri, T. J. Fahey III, A. Zentella, J. D. Albert, G. T. Shires, and A. Cerami. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234:470.
4. Yocum, D., L. Esparza, S. Dubry, J. B. Benjamin, R. Volz, and P. Scuderi. 1989. Characteristics of tumor necrosis factor production in rheumatoid arthritis. Cell. Immunol. 122:131.
5. Macnaul, K. L., N. I. Hutchinson, J. N. Parsons, E. K. Bayne, and M. J. Tocci. 1990. Analysis of IL-1 and TNF-α gene expression in human rheumatoid synoviocytes and normal monocytes by in situ hybridization. J. Immunol. 145:4154.
6. Grau, G. E., L. F. Fajardo, P.-F. Piguet, B. Allet, P.-H. Lambert, and P. Vassalli. 1987. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237:1210.
7. Hofman, F. M., D. R. Hinton, K. Johnson, and J. E. Merrill. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170:607.
8. Selmaj, K., C. S. Raine, B. Cannella, and C. F. Brosnan,. 1991. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87:949.
9. Collart, M. A., P. Baeuerle, and P. Vassalli. 1990. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol. Cell. Biol. 10:1498.
10. Shakhov, A. N., M. A. Collart, P. Vassalli, S. A. Nedospasov, and C. V. Jongeneel. 1990. κB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J. Exp. Med. 171:35.
11. Trede, N. S., A. V. Tsytsykova, T. Chatila, A. E. Goldfeld, and R. S. Geha. 1995. Transcriptional activation of the human TNF-α promoter by superantigen in human monocytic cells: role of NF-κB. J. Immunol. 155:902.
12. Caput, D., B. Beutler, K. Hartog, R. Thayer, S. Brown-Shimer, and A. Cerami. 1986. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. USA 83:1670.
13. Wilson, T., and R. Treisman. 1988. Removal of poly(A) and consequent degradation of c-fos mRNA facilitated by 3′ AU-rich sequences. Nature 336:396.
14. Han, J., T. Brown, and B. Beutler. 1990. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J. Exp. Med. 171:465.
15. Kriegler, M., C. Perez, K. DeFay, I. Albert, and SD. Lu. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53:45.
16. Jue, D.-M., B. Sherry, C. Luedke, K. R. Manogue, and A. Cerami. 1990. Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages. Biochemistry 29:8371.
17. Gearing, A. J. H., P. Beckett, M. Christodoulou, M. Churchill, J. Clements, A. H. Davidson, A. H. Drummond, W. A. Galloway, R. Gilbert, J. L. Gordon, T. M. Leber, M. Mangan, K. Miller, P. Nayee, K. Owen, S. Patel, W. Thomas, G. Wells, L. M. Wood, and K. Woolley. 1994. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 370:555.
18. McGeehan, G. M., J. D. Becherer, R. C. Bast Jr., C. M. Boyer, B. Champion, K. M. Connolly, J. G. Conway, P. Furdon, S. Karp, S. Kidao, A. B. McElroy, J. Nichols, K. M. Pryzwansky, F. Schoenen, L. Sekut, A. Truesdale, M. Verghese, J. Warner, and J. P. Ways. 1994. Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370:558.
19. Mohler, K. M., P. R. Sleath, J. N. Fitzner, D. P. Cerretti, M. Alderson, S. S. Kerwar, D. S. Torrance, C. Otten-Evans, T. Greenstreet, K. Weerawarna, S. R. Kronheim, M. Petersen, M. Gerhart, C. J. Kozlosky, C. J. March, and R. A. Black. 1994. Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 370:218.
20. Isaacson, D., M. Elgart, and M. L. Turner. 1982. Anti-malarials in dermatology. Int. J. Dermatol. 21:379.
21. Gilman, A. G., T. W. Rall, A. S. Nies, and P. Taylor. 1991. Chloroquine and its congeners. In The Pharmacological Basis of Therapeutics, 8th Ed. Pergamon Press, Elmsford, NY, p. 981.
22. Ertel, W., M. H. Morrison, A. Ayala, and I. H. Chaudry. 1991. Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood 78: 1781.
23. Picot, S., F. Peyron, A. Donadille, J.-P. Vuillez, G. Barbe, and P. Ambroise-Thomas. 1993. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 80:127.
24. Zhu, X., W. Ertel, A. Ayala, M. H. Morrison, M. M. Perrin, and I. H. Chaudry. 1993. Chloroquine inhibits macrophage tumor necrosis factor-α mRNA transcription. Immunology 80:122.
25. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione 5-transferase. Gene 67:31.
26. Pennica, D., J. S. Hayflick, T. S. Bringman, M. A. Palladino, and D. V. Goeddel. 1985. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc. Natl. Acad. Sci. USA 82:6060.
27. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55.
28. Ostrove, J. M., and G. E. Gifford. 1979. Stimulation of RNA synthesis in L-929 cells by rabbit tumor necrosis factor. Proc. Soc. Exp. Biol. Med. 160:354.
29. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680.
30. Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475.
31. Sen, R., and D. Baltimore. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46:705.
32. 1. J. Cell Biol. 63:430.
33. Seglen, P. O. 1983. Inhibitors of lysosomal function. Methods Enzymol. 96:737.
34. Seglen, P. O., B. Grinde, and A. E. Solheim. 1979. Inhibition of the lysosomal pathway of protein degradation in isolated rat hepatocytes by ammonia, methylamine, chloroquine, and leupeptin. Eur. J. Biochem. 95:215.
35. Clark, P., E. Casas, P. Tugwell, C. Medina, C. Gheno, G. Tenorio, and J. A. Orozco. 1993. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. Ann. Intern. Med. 119:1067.
36. The HERA study group. 1995. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am. J. Med. 98:156.
37. Vincenti, M. P., T. A. Burrell, and S. M. Taffet. 1992. Regulation of NF-κB activity in murine macrophages: effect of bacterial lipopolysaccharide and phorbol ester. J. Cell. Physiol. 150:204.
38. Xie, Q.-W., Y. Kashiwabara, and C. Nathan. 1994. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269:4705.
39. Kim, H., H. S. Lee, K. T. Chang, T. H. Ko, K. J. Baek, and N. S. Kwon. 1995. Chloromethyl ketones block induction of nitric oxide synthase in murine macrophages by preventing activation of nuclear factor-κB. J. Immunol. 154:4741.
40. Schmitz, M. L., and P. A. Baeuerle. 1991. The p65 subunit is responsible for the strong transcription activating potential of NF-κB. EMBO J. 10:3805.
41. + T lymphocytes. Science 256:1452.
42. Whitehouse, M. W., and F. K. Cowey. 1966. Inhibition of connective tissue proteases by antimalarial, antirheumatic drugs. Biochem. J. 98:11p (Abstr.).
43. Crowe, P. D, B. N. Walter, K. M. Mohler, C. Otten-Evans, R. A. Black, and C. F. Ware. 1995. A metalloproteinase inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J. Exp. Med. 181:1205.
44. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1777.
45. Henter, J.-I., O. Soder, and U. Andersson. 1988. Identification of individual tumor necrosis factor/cachectin-producing cells alter lipopolysaccharide induction. Eur. J. Immunol. 18:983.
46. Maxfield, F. R. 1982. Weak bases and ionophores rapidly and reversibly raise the pH of endocytic vesicles in cultured mouse fibroblasts. J. Cell Biol. 95:676.
47. Kornfeld, R., and S. Kornfeld. 1985. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54:631.
48. 14C]chloroquine by cultured human fibroblasts. Biochem. Pharmacol. 26:7.
49. Osorio, L. M., L. Fonte, and C. M. Finlay. 1992. Inhibition of human monocyte function by prophylactic doses of chloroquine. Am. J. Trop. Med Hyg. 46:165.
50. Ertel, W., M. H. Morrison, A. Ayala, and I. H. Chaudry. 1992. Chloroquine attenuates hemorrhagic shock-induced immunosuppression and decreases susceptibility to sepsis. Arch. Surg. 127:70.
51. Popert, A. J., K. A. E. Meijers, J. Sharp, and F. Bier. 1961. Chloroquine diphosphate in rheumatoid arthritis: a controlled trial. Ann. Rheum. Dis. 20:18.
52. Sams, W. M. 1976. Chloroquine: its therapeutic use in photosensitive eruption. Int. J. Dermatol. 15:99.
53. Cahn, M. M., E. J. Levy, and B. Shaffer. 1956. Polymorphous light eruption: the effect of chloroquine phosphate in modifying reactions to ultraviolet light. J. Invent. Dermatol. 26:201.
54. Grau, G. E., T. E. Taylor, M. Trop, M. E. Molyneux, J. J. Wirima, P. Vassalli, M. Hommel, and P.-H. Lambert. 1989. Tumor necrosis factor and disease severity in children with falciparum malaria. N. Engl. J. Med. 320:1586.
55. Kwiatkowski, D., A. V. S. Hill, I. Sambou, P. Twumasi, J. Castracane, K. R. Manogue, A. Cerami, D. R. Brewster, and B. M. Greenwood. 1990. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 336:1201.
56. McGuire, W., A. V. S. Hill, C. E. M. Allsopp, B. M. Greenwood, and D. Kwjatkowski. 1994. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 371:508.